id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-309934-kcyao9i9	Tan, Emily L.C.	Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs	2004-04-17		.txt	text/plain	3489	180	47	Here we report that certain interferon subtypes exhibit in vitro inhibitory activity against SARS-CoV and are candidates for follow-up studies in animal models and patients to determine their efficacy in vivo. A collection of 19 antiviral drugs was tested in the SARS-CoV CPE inhibition assay ( Table 2) . Because the criteria for ascertaining anti-SARS-CoV activity in this screen were set at 100% inhibition of CPE, and as high doses of interferons may result in severe clinical side effects, we chose to conduct further evaluations only in the interferons that showed complete inhibition from initial screen, namely, Wellferon, Multiferon, Betaferon, and Alferon. Betaferon, Alferon, Multiferon, Wellferon, and ribavirin inhibited CPE in SARS-CoV-infected Vero E6 cells, in decreasing order of potency. Ribavirin, a drug widely used in initial efforts to manage SARS infections, inhibited CPE completely at 500-5,000 µg/mL at virus loads of 100-10,000 PFU per well.	./cache/cord-309934-kcyao9i9.txt	./txt/cord-309934-kcyao9i9.txt